Huge team effort supported by NHSE. Special hat tip 2 Mark Russell @kingscollegelondon.bsky.social who led this project and to all across the OpenSAFELY project!

A starter pack for your perusal - if those are still a thing?!

bsky.app/starter-pack...

And read the paper!
www.bmj.com/content/392/...

The real benefit is that we now have NHS data infrastircture through OpenSAFELY that means we can re run the analysis whenever is needed

"We must no longer accept waiting years to understand disease burden"

As it says in this excellent linked editorial

www.bmj.com/content/392/...

There is important information about health inequalities. Briefly for example e.g. subgroup analyses, diagnosis rates for dementia have increased
above preC19 levels for people of white ethnicity and those from less deprived areas, but not for those from other ethnicities or more deprived areas

This information is really important for continued planning of NHS services.

The @bmj.com have used our data to make even more beautiful charts than we made!

Check them out public.flourish.studio/visualisatio...

Five years on, the recovery varies :

📊 Depression diagnoses are nearly 30% lower than expected (dropping since 2022). 🩸 In contrast, Chronic Kidney Disease (CKD) diagnoses have risen by ~35% above expected levels.

www.bmj.com/content/392/...

Note this is not completely new information. See our earlier OpenSAFELY work in @bjgp.bsky.social

doi.org/10.3399/BJGP...
doi.org/10.3399/BJGP...

And @elife.bsky.social !

elifesciences.org/articles/84673

📉 What did we find?

Diagnosis rates fell sharply for all 19 conditions during the early pandemic.

For example lung diseases (asthma, COPD) and skin conditions (psoriasis, atopic dermatitis) were affected early on.

The scale is phenomenal.

Using anonymised data for 30 million people via the NHS England OpenSAFELY service, we tracked conditions ranging from Asthma & COPD to Heart Failure & Depression & and many more

lol

On a train - lost reliable internet!

Thread another time. Read the paper

www.bmj.com/content/392/...

And the linked editorial

www.bmj.com/content/392/...

So good I listened twice ;)

Audit.
Review.
Improve.

hospitals.openprescribing.net

Remember this is not just a paper that lives on a dusty shelf

Now over to you 👇

Go and check what andexanet alfa use looks like in your hospital on OpenPrescribing.

hospitals.openprescribing.net

It hasn’t been withdrawn in the UK, and there may still be appropriate use cases.

🙏 Massive thanks to the co-authors and collaborators who made this possible.

This kind of transparency and rapid, reproducible analysis is essential if we’re serious about evidence-based and equitable care.

All operating in near real time - available on hospital wards throughout England for live ward round audits!

hospitals.openprescribing.net

This is the first published study using OpenPrescribing Hospitals to analyse adoption of a new hospital medicine.

A LIVE living machine for studying variation, value, and policy impact across the NHS - that is accessible 24/7

hospitals.openprescribing.net

But this paper isn’t really about andexanet alfa.

It’s much bigger than that!